AstraZeneca presented new studies of sementina
Detailed results of the research phase III ADAURA showed that the use of sementina as adjuvant therapy in patients with small cell lung cancer (NSCLC) with mutations in the gene for the receptor of epidermal growth factor (EGFRm) in the early stages (IB, II and IIIA) after complete surgical resection of the tumor provided a statistically and clinically significant increase in disease-free survival (RFS).
Analysis of primary endpoint (RFS in patients with NSCLC II or stage IIIA) showed that adjuvant therapy with sementina led to the reduction of risk of disease recurrence or death by 83%. During the analysis of key secondary endpoints (RFS in the General population of the study in patients with NSCLC IB–IIIA stage) showed a decreasing risk of disease recurrence or death by 79%.
After 2 years, 89% of patients were alive and remained without evidence of disease in the group of sementina and 53% in the placebo group. The advantage of sementina in RFS was observed in all subgroups, including patients who received chemotherapy after surgery, and patients who underwent only surgery, and patients of Asian and non-Asian origin.
